Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
The company signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., to supply its CBD-rich oil from Cannbit strains to be used as part of SCI-210 treatment, last year.SciSparc Ltd. (NASDAQ:SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel.
SciSparc股份有限公司（纳斯达克股票代码：SPRC）在周二宣布，以色列索罗卡医疗中心的孩子们正在进行的自闭症光谱障碍（ASD）临床试验中已经招募和给五名患者使用药品。
What Happened
发生了什么
The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in March to its clinical trial assessing the efficacy and safety of its cannabidiol (CBD)– based drug for the treatment of children with autism spectrum disorder.
这家以色列特殊专科药企专注于开发治疗中枢神经系统疾病的治疗方案，并于今年3月招募了首位参与评估CBD基药物疗法的自闭症光谱障碍患儿。
The double-blind, randomized and placebo-controlled trial uses SciSparc's proprietary SCI-210, a combination of CBD and CannAmide– the company's Palmitoylethanolamide – which is designed to alleviate ASD symptoms. The trial was designed in consultation with the National Autism Research Center.
这项双盲、随机且安慰剂对照的试验使用SciSparc专利的SCI-210，即CBD和CannAmide的组合，后者是该公司的Palmitoylethanolamide，旨在缓解ASD症状，试验是在国家自闭症研究中心的协作下设计的。
The company signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., to supply its CBD-rich oil from Cannbit strains to be used as part of SCI-210 treatment, last year.
该公司去年与以色列的大麻制品生产和分销公司Tikun Olam Cannbit Pharmaceuticals Ltd.签订协议，以供应其来自Cannbit品系的富含CBD的油作为SCI-210治疗的一部分。
Read Also: Cannabis & Children Autism: New Study Claims CBDA Can Help With Behavioral Issues In Kids With ASD
阅读更多：大麻与自闭症：新研究表明CBDA有助于改善ASD患儿的行为问题
Why It Matters
这为以下原因非常重要
"People of all genders, ethnicities and economic backgrounds can be diagnosed with ASD," Oz Adler, SciSparc's CEO said. "Although ASD can be a lifelong disorder, treatments and services can improve a person's symptoms and daily functioning. Consistent with our mission of improving people's lives, we are happy with the ongoing pace of enrollment in the SCI-210 trial and expect that this study will generate new scientific data so that others may be better helped in the future."
SciSparc的首席执行官Oz Adler表示：“所有性别、种族和经济背景的人都可能被诊断出ASD。虽然ASD可能是终身疾病，但治疗和服务可以改善一个人的症状和日常功能。与我们改善人们生活的使命一致，我们对SCI-210试验的招募进度感到满意，并期望这项研究将产生新的科学数据，以便未来的治疗更加有效。”
What's Next
接下来怎么做
The company plans to enroll 60 subjects between the ages of five and eighteen for twenty weeks, to assess how SCI-210 therapy compares to standard CBD monotherapy in managing symptoms of ASD.
该公司计划招募5至18岁之间的60名患者进行为期20周的SCI-210疗法评估，以评估SCI-210疗法与标准CBD单药疗法在控制ASD症状方面的差异。
SciSparc seeks to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
SciSparc寻求首先在以色列，随后在其他国家销售SCI-210，前提是获得所需的监管批准。
Now read:
现在阅读：
- Cannabis Can Be A Game-Changer For Improving The Lives Of Autistic Adults
- 大麻可以成为改善自闭症成人生活的游戏规则改变者
SPRC Price Action
SPRC价格动态
SciSparc's shares traded 0.8333% higher at $0.4235 per share at the time of writing on Tuesday morning.
科思创股份有限公司（SciSparc）的股价于周二上午撰写本文时上涨0.8333％，为每股0.4235美元。
